Provided by Tiger Fintech (Singapore) Pte. Ltd.

Organon & Co

9.76
+0.20002.09%
Post-market: 9.850.0900+0.92%18:21 EDT
Volume:3.89M
Turnover:38.38M
Market Cap:2.54B
PE:3.39
High:10.05
Open:9.60
Low:9.58
Close:9.56
Loading ...

Press Release: Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

Dow Jones
·
15 Apr

Organon & Co - Expects $6 Million Milestone Expense in Q1 2025

THOMSON REUTERS
·
15 Apr

Health Canada Approves Nduvra™ (Tapinarof Cream), 1%, for the Topical Treatment of Plaque Psoriasis in Adults

THOMSON REUTERS
·
14 Apr

Morgan Stanley Sticks to Its Hold Rating for Organon (OGN)

TIPRANKS
·
09 Apr

Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment

StockStory
·
08 Apr

Why Organon (OGN) Could Beat Earnings Estimates Again

Zacks
·
03 Apr

Organon Acquires Tofidence for Intravenous Infusion in US

MT Newswires Live
·
01 Apr

Organon & Co - to Pay Tiered Royalties and Milestone Payments to Biogen

THOMSON REUTERS
·
01 Apr

Organon Acquires Tofidence™ (Tocilizumab-Bavi), a Commercialized Biosimilar to Actemra® (Tocilizumab) Injection, for Intravenous Infusion in the U.S.

THOMSON REUTERS
·
01 Apr

Organon & Co - Bio-Thera Solutions to Maintain Manufacturing Rights for Tofidence

THOMSON REUTERS
·
01 Apr

Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug

MT Newswires Live
·
28 Mar

BRIEF-European Medicines Agency (EMA) Validates Henlius And Organon Filing For Perjeta® (Pertuzumab) Biosimilar Candidate HLX11

Reuters
·
28 Mar

European Medicines Agency (Ema) Validates Henlius and Organon Filing for Perjeta® (Pertuzumab) Biosimilar Candidate Hlx11

THOMSON REUTERS
·
28 Mar

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Business Wire
·
28 Mar

Barclays Sticks to Its Buy Rating for Organon (OGN)

TIPRANKS
·
10 Mar

May Health Appoints Seasoned Medtech Executive, Colby Holtshouse, as President and CEO

THOMSON REUTERS
·
10 Mar

Organon announes results from analysis of Phase 3 ADORING 3 study

TIPRANKS
·
10 Mar

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

Business Wire
·
08 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Organon (OGN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
06 Mar

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Simply Wall St.
·
17 Feb